Checkpoint Therapeutics Past Earnings Performance
Past criteria checks 0/6
Checkpoint Therapeutics's earnings have been declining at an average annual rate of -20.2%, while the Biotechs industry saw earnings growing at 12.3% annually. Revenues have been declining at an average rate of 66.7% per year.
Key information
-20.2%
Earnings growth rate
20.2%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | -66.7% |
Return on equity | n/a |
Net Margin | -50,336.9% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
We're A Little Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate
Sep 20Checkpoint: Strong Data, But Comes With Risks
Sep 08Checkpoint Therapeutics GAAP EPS of -$0.16 in-line, revenue of $0.02M beats by $0.01M
Aug 12Is Checkpoint Therapeutics (NASDAQ:CKPT) In A Good Position To Deliver On Growth Plans?
May 18Checkpoint Therapeutics: Potential Upside Based On Marketing Application Submissions
Apr 18Companies Like Checkpoint Therapeutics (NASDAQ:CKPT) Are In A Position To Invest In Growth
Feb 15Checkpoint Therapeutics: Another Buying Opportunity Following Cosibelimab's Impressive Topline Results
Jan 28Checkpoint Therapeutics: Pullback Provides Opportunity To Add Ahead Of Cosibelimab's Data Readout
Nov 26Checkpoint Therapeutics (NASDAQ:CKPT) Is In A Good Position To Deliver On Growth Plans
Oct 30We're Not Very Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate
Jul 17Checkpoint Therapeutics: Amassing A Position Ahead Of Cosibelimab Data
Jul 14Checkpoint Therapeutics (CKPT) Investor Presentation - Slideshow
Jun 21Checkpoint surges 24% on B. Riley buy initiation, 567% upside potential
Jun 09It's Unlikely That Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) CEO Will See A Huge Pay Rise This Year
Jun 02The Checkpoint Therapeutics (NASDAQ:CKPT) Share Price Is Up 141% And Shareholders Are Boasting About It
Mar 11Have Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Insiders Been Selling Their Stock?
Feb 06Do Institutions Own Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Shares?
Jan 27Companies Like Checkpoint Therapeutics (NASDAQ:CKPT) Are In A Position To Invest In Growth
Dec 23What We Learned About Checkpoint Therapeutics' (NASDAQ:CKPT) CEO Pay
Nov 27Checkpoint Therapeutics +10% after expanding cosibelimab manufacturing deal with Samsung Biologics
Nov 02Revenue & Expenses BreakdownBeta
How Checkpoint Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -52 | 9 | 0 |
30 Sep 23 | 0 | -54 | 9 | 0 |
30 Jun 23 | 0 | -59 | 9 | 0 |
31 Mar 23 | 0 | -56 | 9 | 0 |
31 Dec 22 | 0 | -63 | 9 | 0 |
30 Sep 22 | 0 | -71 | 8 | 0 |
30 Jun 22 | 0 | -72 | 8 | 0 |
31 Mar 22 | 0 | -67 | 8 | 0 |
31 Dec 21 | 0 | -57 | 9 | 0 |
30 Sep 21 | 0 | -37 | 9 | 0 |
30 Jun 21 | 0 | -31 | 9 | 0 |
31 Mar 21 | 0 | -26 | 9 | 0 |
31 Dec 20 | 1 | -23 | 8 | 0 |
30 Sep 20 | 1 | -22 | 8 | 0 |
30 Jun 20 | 1 | -22 | 7 | 0 |
31 Mar 20 | 2 | -22 | 7 | 0 |
31 Dec 19 | 2 | -25 | 7 | 0 |
30 Sep 19 | 5 | -28 | 7 | 0 |
30 Jun 19 | 4 | -32 | 7 | 0 |
31 Mar 19 | 4 | -33 | 6 | 0 |
31 Dec 18 | 4 | -36 | 7 | 0 |
30 Sep 18 | 1 | -31 | 6 | 0 |
30 Jun 18 | 1 | -27 | 6 | 0 |
31 Mar 18 | 1 | -27 | 6 | 0 |
31 Dec 17 | 2 | -23 | 5 | 0 |
30 Sep 17 | 2 | -25 | 5 | 0 |
30 Jun 17 | 2 | -24 | 5 | 0 |
31 Mar 17 | 3 | -23 | 5 | 0 |
31 Dec 16 | 3 | -22 | 4 | 0 |
30 Sep 16 | 2 | -22 | 6 | -2 |
30 Jun 16 | 2 | -21 | 5 | -2 |
31 Mar 16 | 0 | -16 | 4 | 0 |
31 Dec 15 | 1 | -14 | 2 | 0 |
Quality Earnings: CKPT is currently unprofitable.
Growing Profit Margin: CKPT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CKPT is unprofitable, and losses have increased over the past 5 years at a rate of 20.2% per year.
Accelerating Growth: Unable to compare CKPT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CKPT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: CKPT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.